Lantern Pharma Inc.LTRNNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | -0.87% | -0.15% | +0.39% | +0.24% | +0.65% |
| Weighted Average Shares Diluted Growth | -0.87% | -0.15% | +0.39% | +0.24% | +0.65% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -100.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -36.59% | -41.41% | -46.91% | -51.05% | -55.02% |
| Book Value per Share Growth | -40.92% | -48.13% | -53.28% | -59.61% | -64.19% |
| Debt Growth | +6.09% | +3.92% | +0.70% | -33.68% | -67.74% |
| R&D Expense Growth | +68.18% | +19.49% | -23.22% | -21.10% | -34.43% |
| SG&A Expenses Growth | +11.36% | +25.07% | +1.95% | +4.20% | +30.47% |